Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.930.02%
QQQ
707.830.03%
BTC/USD
77310.200.1064%
DIA
527.670.02%
GLD
396.500.06%
TLT
81.830.05%

Lantern Pharma Inc

LTRNNASDAQ
Trade with Public
Trade with Public
$2.02
-0.01-0.49%
At close: Sep 1, 5:00 PM EST
$2.02
N/A
After Hours: 4:48 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Lantern Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lantern Pharma (LTRN).

Price Target Range — 1 Quarters

Analyst Consensus — 2 Analysts

1Buy
1Hold
Consensus RatingBuy# Analysts2Avg. Consensus PT$25Upside to Avg. PT+1137.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Apr 2, 2025Lake StreetChad MesserInitiateBuy$25
Apr 25, 2024HC Wainwright & Co.Emily BodnarMaintainedNeutral—

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

Lake Street analyst Chad Messer initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $25.
Benzinga Newsdesk

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.
Benzinga Newsdesk

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08102023_LTRN_Vandermosten.pdf
Happy Mohamed

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

EF Hutton analyst Michael King reiterates Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.
Benzinga Newsdesk

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

EF Hutton analyst Michael King maintains Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved